- Home
- MIN vs HUMA Comparison
MIN vs HUMA Comparison
Compare MIN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIN | HUMA |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.8M | 308.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MIN | HUMA |
|---|---|---|
| Price | $2.46 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 144.1K | ★ 16.5M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | $30.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $0.55 |
| 52 Week High | $2.72 | $2.84 |
Technical Indicators
Market Signals| Indicator | MIN | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 44.39 |
| Support Level | $2.41 | $0.60 |
| Resistance Level | $2.49 | $1.28 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 41.67 | 29.14 |
Price Performance
Historical ComparisonAbout MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.